IBDEI0NQ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11681,2)
 ;;=^123842
 ;;^UTILITY(U,$J,358.3,11682,0)
 ;;=573.9^^79^765^21
 ;;^UTILITY(U,$J,358.3,11682,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11682,1,1,0)
 ;;=1^573.9
 ;;^UTILITY(U,$J,358.3,11682,1,2,0)
 ;;=2^OTHER LIVER DISEASE
 ;;^UTILITY(U,$J,358.3,11682,2)
 ;;=^123854
 ;;^UTILITY(U,$J,358.3,11683,0)
 ;;=580.9^^79^766^1
 ;;^UTILITY(U,$J,358.3,11683,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11683,1,1,0)
 ;;=1^580.9
 ;;^UTILITY(U,$J,358.3,11683,1,2,0)
 ;;=2^ACUTE GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,11683,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,11684,0)
 ;;=584.9^^79^766^2
 ;;^UTILITY(U,$J,358.3,11684,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11684,1,1,0)
 ;;=1^584.9
 ;;^UTILITY(U,$J,358.3,11684,1,2,0)
 ;;=2^ACUTE RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,11684,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,11685,0)
 ;;=582.9^^79^766^3
 ;;^UTILITY(U,$J,358.3,11685,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11685,1,1,0)
 ;;=1^582.9
 ;;^UTILITY(U,$J,358.3,11685,1,2,0)
 ;;=2^CHRONIC GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,11685,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,11686,0)
 ;;=585.9^^79^766^4
 ;;^UTILITY(U,$J,358.3,11686,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11686,1,1,0)
 ;;=1^585.9
 ;;^UTILITY(U,$J,358.3,11686,1,2,0)
 ;;=2^CHRONIC KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,11686,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,11687,0)
 ;;=586.^^79^766^5
 ;;^UTILITY(U,$J,358.3,11687,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11687,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,11687,1,2,0)
 ;;=2^OTHER RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,11687,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,11688,0)
 ;;=694.9^^79^767^1
 ;;^UTILITY(U,$J,358.3,11688,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11688,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,11688,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,11688,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,11689,0)
 ;;=695.10^^79^767^2
 ;;^UTILITY(U,$J,358.3,11689,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11689,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,11689,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,11689,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,11690,0)
 ;;=696.1^^79^767^3
 ;;^UTILITY(U,$J,358.3,11690,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11690,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,11690,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,11690,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,11691,0)
 ;;=695.81^^79^767^4
 ;;^UTILITY(U,$J,358.3,11691,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11691,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,11691,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,11691,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,11692,0)
 ;;=695.13^^79^767^5
 ;;^UTILITY(U,$J,358.3,11692,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11692,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,11692,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,11692,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,11693,0)
 ;;=695.15^^79^767^6
 ;;^UTILITY(U,$J,358.3,11693,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11693,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,11693,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,11693,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,11694,0)
 ;;=695.9^^79^767^7
 ;;^UTILITY(U,$J,358.3,11694,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11694,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,11694,1,2,0)
 ;;=2^OTHER ERYTHEMATOUS SKIN COND
 ;;^UTILITY(U,$J,358.3,11694,2)
 ;;=^123902
 ;;^UTILITY(U,$J,358.3,11695,0)
 ;;=441.9^^79^768^2
 ;;^UTILITY(U,$J,358.3,11695,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11695,1,1,0)
 ;;=1^441.9
